42048-25-9

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 104-86-9 4-chlorobenzylamine 
• 3723-71-5 2-(4-chlorophenylmethylamino)-3-nitropyridine 

Downstream Products

• 136122-61-7 4-[3-(4-Chloro-benzyl)-3H-imidazo[4,5-b]pyridin-2-ylsulfanyl]-butyric acid ethyl ester 
• 144727-86-6 4-[3-(4-Chloro-benzyl)-3H-imidazo[4,5-b]pyridin-2-yl]-3,3-dimethyl-butyric acid ethyl ester 
• 136122-54-8 3-(4-Chloro-benzyl)-3H-imidazo[4,5-b]pyridine-2-thiol 

Relevant academic research and scientific papers

Heterocyclic compounds having anti-diabetic activity and their use

Compounds of formula (I): STR1 [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.

Synthesis and Structure - Activity Relationships of Novel Benzimidazole and Imidazopyridine Acid Derivatives as Thromboxane A2 Receptor Antagonists

A series of 1-benzylbenzimidazole and 3-benzylimidazopyridine substituted in the 2-position by an alkanoic or mercaptoalkanoic acid chain was synthesized for evaluation as potential thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonists.T